Healthcare stocks have had a rough stretch. Rising medical costs, Medicaid pressure, and persistent skepticism about managed care margins have kept investors on edge all year.
Walking into a CVS Health earnings report in that environment felt like bracing for bad news. The bad news, however, didn’t come.
CVS Health (CVS) posted first-quarter 2026 adjusted EPS of $2.57, according to its earnings report, blowing past both Morgan Stanley’s $2.17 estimate and the $2.18 consensus by 40 cents.
The company raised its full-year adjusted EPS guidance by 30 cents at the midpoint. And the number that matters most to managed care investors — the medical benefit ratio- came in significantly better than expected.
“With another MLR beat in MCO-land, we view the shares should grind higher on the print,” Morgan Stanley (MS) said in a note shared with me at TheStreet.
That is a measured but meaningful statement from a firm that has been navigating a complicated healthcare sector all year.
CVS Health’s Q1 2026 results beat across the metrics that matter most
The headline numbers from CVS’s May 6 earnings release:
- Total revenues of $100.4 billion, up 6.2% year over year
- Adjusted EPS of $2.57, beating consensus by 39 cents
- GAAP diluted EPS of $2.30
- Cash flow from operations guidance raised to at least $9.5 billion from $9.0 billion
- Full-year adjusted EPS guidance raised to $7.30 to $7.50 from $7.00 to $7.20
Source: CVS Health Corporation first-quarter 2026 results earnings release..
The medical benefit ratio came in at 84.6%, well below the Morgan Stanley estimate of 86.0% and the 86.2% consensus, according to the note shared.
For managed care investors, the MLR is the single most watched number in any quarterly print – it measures the share of premium revenue spent on medical claims. Lower is better. 84.6% is meaningfully better.
My read of that 160-basis-point beat versus consensus is that CVS’s medical cost management held up more effectively than the market feared heading into the quarter.
In an environment where peers have been struggling with elevated utilization, that is a genuine competitive signal.
CVS Health Services segment delivered a surprise most analysts didn’t see coming
Beyond the MLR, the segment that commanded the most investor attention was Health Services, CVS’s pharmacy benefit management and specialty care division, which has been under pressure from PBM industry volatility.
Health Services adjusted operating income growth came in at -7.1% year over year. That sounds weak until you compare it to what was expected: consensus was modeling negative 16.7%, and Morgan Stanley’s own estimate was negative 18.7%, according to the Morgan Stanley note shared with me at TheStreet.
More Health Care:
- If your Medicare plan was canceled, do this now
- Health care costs are the wild card in year-end tax planning
- 22 million Americans hit by ACA health insurance cliff after vote fails
My review of the segment gap provides the key insights here. CVS didn’t just beat Health Services. It beat by roughly 1,000 basis points versus consensus.
Morgan Stanley management noted the result reflects “early recognition of value that was previously expected to occur in the second quarter.” Even excluding that timing benefit, results modestly exceeded CVS’s own internal expectations.
The one soft spot was Pharmacy and Consumer Wellness, where adjusted operating income growth came in at negative 8.8% against a consensus expectation of negative 4.0%. Management attributed the miss partly to seasonal factors, flu dynamics, and weather-related headwinds, timing issues, rather than structural deterioration.
CVS also raised guidance and expanded medical membership
The guidance raise is the part of the CVS story that Morgan Stanley wants investors to focus on.
- Full-year 2026 adjusted EPS guidance is now $7.30 to $7.50, up from $7.00 to $7.20
- Cash flow from operations guidance rose to at least $9.5 billion
- Medical membership of approximately 26.0 million, up from the prior 25.6 million forecast. Still reflecting a 2% year-over-year decline, but meaningfully better than the 3.5% decline previously embedded in guidance.
Source: CVS Health Corporation First-Quarter 2026 Results.
What Morgan Stanley flagged as notable is that the 30-cent midpoint guidance raise does not fully pass through the 40-cent first-quarter beat. That gap implies CVS is building in conservatism for the rest of the year, specifically holding its full-year MLR target unchanged at 90.5% plus or minus 50 basis points.
The company is not assuming the favorable first-quarter medical cost experience repeats automatically. That conservatism, in this environment, reads as credibility.
What CVS’s beat means for investors
CVS Health CEO David Joyner framed the company’s position in direct terms, as seen in the earnings release.
“We build trust every day in communities across the country by providing better access, affordability, and care to nearly 185 million people,” Joyner said. “Our positive performance is driven by strong execution across our enterprise.”
For investors, the first-quarter print resolves at least one major overhang. The fear heading into CVS earnings was that medical cost trends were deteriorating faster than the company’s pricing could absorb. The 84.6% MLR says that fear, at least for now, was overblown.
Morgan Stanley’s “grind higher” language is deliberate. This is not a call for a dramatic re-rating. It is a call for a stock that has been penalized by managed-care-sector anxiety to begin recovering as earnings evidence accumulates.
One strong quarter does not erase a difficult environment. But it changes the narrative, and in this sector, narrative shifts matter.
Related: Bank of America resets future estimates for CVS post earnings
